Phospho-TOP2A (T1343) Antibody

What is the TOP2A protein and what function does phosphorylation at T1343 serve?

TOP2A (DNA topoisomerase 2-alpha) is a key decatenating enzyme that alters DNA topology through a complex mechanism. It functions by binding to two double-stranded DNA molecules, generating a double-stranded break in one strand, passing the intact strand through the broken strand, and finally religating the broken strand . The enzyme plays crucial roles in DNA replication, transcription, and chromosome segregation during mitosis.

The phosphorylation at threonine 1343 (T1343) occurs in the C-terminal domain (CTD) of TOP2A, a region that is predicted to be intrinsically disordered but involved in enzyme regulation . Research indicates that mutations in the region containing T1343 (specifically 1324-1343) produce 2-3 times more DNA cleavage in the presence of etoposide than wild-type TOP2A, suggesting this phosphorylation site may regulate the enzyme's catalytic activity .

What are the key characteristics of Phospho-TOP2A (T1343) antibodies available for research?

Most commercial Phospho-TOP2A (T1343) antibodies share these specifications:

These antibodies are specifically designed to detect endogenous levels of TOP2A protein only when phosphorylated at the T1343 position .

What are the optimal conditions for using Phospho-TOP2A (T1343) antibody in Western blot experiments?

For Western blot experiments, follow these methodological guidelines:

• Sample preparation: Cells or tissues should be lysed in a buffer containing phosphatase inhibitors to preserve phosphorylation states. Freshly prepared samples yield best results.

• Dilution range: Most manufacturers recommend a dilution range of 1:500-1:2000 for Western blot applications . Initial optimization at 1:1000 is a good starting point.

• Validation controls: Include both phosphatase-treated negative controls and appropriately stimulated positive controls. For T1343 phosphorylation, cells treated with Ca²⁺ (40nM for 30 minutes) have been shown to enhance the phosphorylation signal .

• Loading controls: Use appropriate loading controls and total TOP2A antibody in parallel blots to normalize phospho-specific signals.

• Detection method: Use a blocking peptide competition assay to confirm specificity - the phospho-peptide should block the signal as demonstrated in validation images from vendors .

Evidence from validation studies shows clear bands at approximately 170-174 kDa (matching TOP2A's molecular weight of 174385 Da) .

How can I optimize immunofluorescence experiments using Phospho-TOP2A (T1343) antibodies?

For immunocytochemistry/immunofluorescence applications:

• Fixation method: Use 4% paraformaldehyde fixation followed by permeabilization with 0.1% Triton X-100 for optimal epitope preservation and accessibility .

• Antibody dilution: Start with a dilution of 1:50 to 1:100, with 1:50 being recommended for initial trials .

• Antigen retrieval: For formalin-fixed paraffin-embedded tissues, heat-mediated antigen retrieval with citrate buffer (pH 6.0) is recommended before commencing the IHC staining protocol .

• Counter-staining: Use nuclear stains like DAPI to visualize the nuclei, and consider co-staining with markers like alpha-tubulin (using non-cross-reactive antibody species) to visualize cell structures .

• Imaging parameters: Use confocal microscopy for optimal visualization of nuclear localization, as TOP2A is predominantly localized to the nucleus during most cell cycle phases.

Validation images show that phosphorylated TOP2A at T1343 displays predominantly nuclear localization in cell lines such as HeLa .

How does phosphorylation at T1343 affect TOP2A function compared to other phosphorylation sites?

TOP2A contains multiple phosphorylation sites with distinct effects on enzyme function:

• T1343 phosphorylation: Located in the C-terminal domain (1324-1343 region), this modification appears to influence enzyme activity, as mutations in this region increase etoposide-induced DNA cleavage by 2-3 fold . This suggests that phosphorylation at T1343 may regulate DNA cleavage activity.

• S1106 phosphorylation: Unlike T1343, phosphorylation at S1106 by CSNK1D/CK1 has been directly shown to promote DNA cleavable complex formation .

• S1213 phosphorylation: Another site that may have distinct regulatory functions, though its specific effects are less well characterized than other sites .

• S1525 phosphorylation: Located in the ChT (Chromatin Tether) domain (1500-1531), this site is regulated by multiple kinases including PLK1, CKII, and p38γ (MAPK12), and is implicated in G2/M decatenation checkpoint function .

The table below compares the functional impact of these phosphorylation sites:

These differential phosphorylation events likely contribute to the fine-tuning of TOP2A activity throughout the cell cycle and in response to different cellular stresses.

What is the relationship between T1343 phosphorylation and cancer development or treatment response?

The relationship between TOP2A phosphorylation at T1343 and cancer involves several aspects:

• Cancer biomarker potential: TOP2A expression is upregulated in several cancer types, including lung adenocarcinoma, where it correlates with poor prognosis . Although general TOP2A expression serves as a biomarker, the specific role of phosphorylation at T1343 in cancer progression requires further investigation.

• Therapeutic implications: The C-terminal domain of TOP2A, where T1343 is located, differs between the two human TOP2 isoforms (TOP2A and TOP2B), suggesting that targeting this phosphorylation site might provide a means for selectively inhibiting TOP2A for therapeutic purposes .

• Chemotherapy response: Since mutations in the 1324-1343 region increase etoposide-induced DNA cleavage, the phosphorylation status at T1343 might influence the efficacy of TOP2A-targeting chemotherapeutics like etoposide .

• Resistance mechanisms: TOP2A is implicated in drug resistance of tumor cells , and phosphorylation-mediated regulation might play a role in this resistance by altering enzyme activity or interactions with drugs.

Research showing that knockdown of TOP2A in A549 lung adenocarcinoma cells downregulates proliferation and increases apoptosis suggests that targeting TOP2A (and potentially its phosphorylation) might have therapeutic value .

What are common technical challenges when working with Phospho-TOP2A (T1343) antibodies and how can they be addressed?

Researchers frequently encounter these challenges when working with phospho-specific antibodies like Phospho-TOP2A (T1343):

• Weak or absent signal in Western blot:

  • Potential cause: Phosphatase activity during sample preparation

  • Solution: Use fresh phosphatase inhibitors in lysis buffers and keep samples cold throughout processing

  • Methodological approach: Consider enriching phosphorylated proteins using phospho-protein enrichment kits before Western blotting

• High background or non-specific binding:

  • Potential cause: Insufficient blocking or antibody cross-reactivity

  • Solution: Optimize blocking conditions (5% BSA is often better than milk for phospho-epitopes) and increase washing steps

  • Validation approach: Run a blocking peptide competition assay to confirm specificity - the phospho-peptide should block the signal as demonstrated in vendor validation images

• Inconsistent results between experiments:

  • Potential cause: Cell cycle-dependent phosphorylation or variation in culture conditions

  • Solution: Synchronize cells if studying cell cycle-dependent phosphorylation events, as TOP2A phosphorylation varies throughout the cell cycle

  • Experimental design: Include positive controls with known phosphorylation status in each experiment

• Discrepancies between different detection methods:

  • Potential cause: Epitope accessibility differs between applications

  • Solution: Optimize protocols specifically for each application (WB, IF, IHC) rather than using identical conditions

  • Verification approach: Use multiple antibodies targeting different epitopes of TOP2A to confirm results

How should researchers interpret conflicting data regarding TOP2A phosphorylation in different experimental systems?

When faced with conflicting data regarding TOP2A phosphorylation:

• Consider cell type-specific regulation: TOP2A phosphorylation patterns may differ between cell types due to variations in kinase activity or regulatory mechanisms. For example, cancer cells often show altered phosphorylation patterns compared to normal cells .

• Evaluate cell cycle dependencies: TOP2A phosphorylation is highly cell cycle-dependent, with many sites specifically phosphorylated during mitosis or G2/M transition . Differences in cell synchronization methods can lead to apparently conflicting results.

• Assess experimental conditions that affect phosphorylation:

  • Serum starvation/stimulation

  • DNA damage agents

  • Kinase/phosphatase inhibitors

  • Cell density and growth conditions

• Analyze antibody cross-reactivity: Some phospho-specific antibodies may recognize similar phosphorylation motifs. Validate specificity through:

  • Phosphatase treatment controls

  • Phospho-blocking peptides

  • Phospho-site mutants (T1343A)

• Integration of multiple techniques: Combine different approaches (Western blot, mass spectrometry, immunofluorescence) to obtain a more comprehensive understanding of phosphorylation events.

When specifically assessing T1343 phosphorylation, results from both polyclonal and monoclonal antibodies should be compared for consistency.

What research questions remain unsolved regarding the regulation and function of TOP2A phosphorylation at T1343?

Several critical research questions about T1343 phosphorylation warrant further investigation:

• Kinase identification and regulation: While the T1343 site is known to be phosphorylated, the specific kinase(s) responsible requires definitive identification. Preliminary data suggests potential involvement of CKII and PLK3 kinases at the G2/M transition , but comprehensive kinase profiling is needed.

• Structural consequences: How does phosphorylation at T1343 alter the conformation of the C-terminal domain and its interaction with DNA? This question is particularly interesting given that the C-terminal domain is predicted to be intrinsically disordered .

• Interaction networks: Does phosphorylation at T1343 modify TOP2A's interaction with other proteins or complexes? Analysis of differential protein binding between phosphorylated and non-phosphorylated forms could reveal regulatory mechanisms.

• Cross-talk with other modifications: TOP2A undergoes various post-translational modifications including SUMOylation and ubiquitination . The interplay between T1343 phosphorylation and these modifications remains poorly understood.

• Physiological triggers: What cellular signals or stresses specifically induce or reduce T1343 phosphorylation? Systematic analysis of various cellular perturbations could identify specific regulatory pathways.

How can studies of Phospho-TOP2A (T1343) contribute to the development of novel cancer therapeutics?

The potential of Phospho-TOP2A (T1343) research for cancer therapeutic development includes:

• Isoform-specific targeting: The C-terminal domain of TOP2A, where T1343 is located, differs significantly from TOP2B . Understanding how phosphorylation affects this region could lead to the development of isoform-specific inhibitors, potentially reducing off-target effects of current topoisomerase inhibitors.

• Biomarker development: The phosphorylation status of T1343 could serve as a biomarker for:

  • Cancer progression

  • Treatment response prediction

  • Patient stratification for TOP2A-targeting therapies

• Synthetic lethality approaches: Identifying genes and pathways that show synthetic lethality with altered T1343 phosphorylation could reveal new therapeutic targets, particularly in cancers with deregulated TOP2A.

• Combination therapy optimization: Understanding how T1343 phosphorylation affects drug-induced DNA damage could inform the development of more effective combination therapies with existing TOP2A poisons like etoposide.

• Regulation of drug resistance: Given that mutations in the 1324-1343 region affect etoposide-induced DNA cleavage , modulating T1343 phosphorylation might help overcome resistance to TOP2A-targeting drugs.

Research demonstrating that TOP2A knockdown decreases proliferation and increases apoptosis in lung adenocarcinoma cells highlights the therapeutic potential of targeting TOP2A and its regulatory mechanisms, including the phosphorylation of sites like T1343.

What are the most effective experimental designs for investigating the functional significance of T1343 phosphorylation?

To rigorously investigate T1343 phosphorylation function, consider these methodological approaches:

• Site-directed mutagenesis studies:

  • Generate phospho-mimetic (T1343D/E) and phospho-deficient (T1343A/G) mutants

  • Express in TOP2A-depleted backgrounds to avoid interference from endogenous protein

  • Compare biochemical activities (DNA binding, cleavage, relaxation, decatenation) as demonstrated in research on other TOP2A residues

• CRISPR-Cas9 genome editing:

  • Engineer cell lines with endogenous T1343A or T1343D/E mutations

  • Analyze phenotypic consequences on cell cycle progression, chromosome segregation, and DNA damage response

  • Compare with wild-type cells under various stress conditions

• Chemical genetics approach:

  • Identify specific kinase(s) responsible for T1343 phosphorylation using kinase inhibitor panels

  • Develop analog-sensitive kinase systems to specifically modulate T1343 phosphorylation

  • Correlate phosphorylation status with functional outcomes

• Structural biology:

  • Use NMR spectroscopy or hydrogen-deuterium exchange mass spectrometry to analyze structural changes induced by phosphorylation

  • Focus on how phosphorylation affects the intrinsically disordered C-terminal domain interactions

• Temporal analysis:

  • Employ synchronized cell populations to track T1343 phosphorylation throughout the cell cycle

  • Correlate with TOP2A activity and chromatin association

  • Use live-cell imaging with phospho-specific sensors if possible

The experimental design should include appropriate controls and validation steps using the phospho-specific antibodies discussed throughout this document.

What cutting-edge technologies are advancing our understanding of TOP2A phosphorylation biology?

Several advanced technologies are transforming TOP2A phosphorylation research:

• Proximity labeling proteomics:

  • BioID or APEX2 fusion constructs can identify proteins that differentially interact with phosphorylated versus non-phosphorylated TOP2A

  • This approach has advantages over conventional immunoprecipitation for capturing transient interactions

• Mass spectrometry-based phosphoproteomics:

  • Parallel Reaction Monitoring (PRM) allows precise quantification of phosphorylation stoichiometry

  • Middle-down proteomics can identify combinatorial patterns of multiple modifications on TOP2A

  • Crosslinking mass spectrometry can reveal structural changes induced by phosphorylation

• Single-molecule techniques:

  • Optical tweezers or magnetic tweezers to directly measure how T1343 phosphorylation affects TOP2A's mechanical activity on individual DNA molecules

  • Super-resolution microscopy to track phosphorylated TOP2A localization with nanometer precision

• Protein engineering approaches:

  • Optogenetic tools to control T1343 phosphorylation status with light

  • Conditionally destabilized TOP2A mutants for rapid protein regulation

• Computational biology:

  • Molecular dynamics simulations to predict structural consequences of phosphorylation

  • Machine learning algorithms to identify patterns in phosphorylation data across cancer types